Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Single-session, same day, combined selective transarterial embolization and microwave ablation of large renal masses has been demonstrated to be safe and efficacious in the short-term. Herein we report the outcomes of patients treated with this novel therapeutic technique at a single academic medical center after five years of experience.
Abstract No. 244 Determination of tumor dose response threshold and implication on survival in patients with metastatic uveal melanoma to the liver undergoing yttrium-90 radioembolization
D. Madoff J. Llovet A. El-Khoueiry M. Kudo R. Finn S. Ogasawara Z. Ren A. Vogel Limited treatment options are available for patients with intermediate hepatocellular carcinoma (HCC). Lenvatinib, a potent multikinase inhibitor, and pembrolizumab, a programmed death receptor-1 blocking antibody, are approved first- and second-line therapies for advanced HCC, respectively.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.